← Leaderboards
David J Kroll
Duke University
$3,224,190
Attributed
$3,224,190
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $663.4K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$3,224,190 · 4
By mechanism
R01$2,433,425 · 2
R21$558,639 · 1
R25$232,126 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Neoplasm /Cancer Pharmacology”
- Constance Ann Benson · University Of California, San Diego$110,607,997
- Gregory H Reaman · National Childhood Cancer Foundation$80,145,837
- Richard L Schilsky · University Of Chicago$72,058,991
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Leland H Hartwell · Fred Hutchinson Cancer Research Center$22,238,492
- Philip J Disaia · University Of California Irvine$19,978,203
Research focus
Neoplasm /Cancer PharmacologyPhosphorylationCell CycleDna GyraseEtoposideEnzyme ActivityGene MutationPosttranslational ModificationsTissue /Cell CultureProtein Protein InteractionHigh Performance Liquid ChromatographyIsozymesMitochondriaMultiple MyelomaDna DamageCell LinePhosphoproteinsPlasmidsDrug ResistanceNeoplasm /Cancer ChemotherapyAthymic MouseMass SpectrometryFlavonoidsBiological Products
Grant awards (11)
NORTH CAROLINA CENTRAL UNIVERSITY EAGLES RISE WITH MENTORING THROUGH THE DOCTORAL$232,126
R25 · FY2010 · GM · contact PI
Pure Flavonolignans from S. marianum in Prostate Cancer$383,269
R01 · FY2007 · CA · contact PI
Pure Flavonolignans from S. marianum in Prostate Cancer$383,850
R01 · FY2006 · CA · contact PI
Pure Flavonolignans from S. marianum in Prostate Cancer$382,273
R01 · FY2005 · CA
Formulation Dependent Help Interactions with Chemothera*$281,126
R21 · FY2005 · CA
Pure Flavonolignans from S. marianum in Prostate Cancer$366,377
R01 · FY2004 · CA
Formulation Dependent Help Interactions with Chemothera*$277,513
R21 · FY2004 · CA
14 3 3 Implications in Topoisomerase II Pharmacology$325,736
R01 · FY2003 · CA
14 3 3 Implications in Topoisomerase II Pharmacology$325,697
R01 · FY2002 · CA
14 3 3 Implications in Topoisomerase II Pharmacology$140,484
R01 · FY2001 · CA
14 3 3 Implications in Topoisomerase II Pharmacology$125,739
R01 · FY2001 · CA